Windham Venture Partners

@windhamvp

October 14, 2021

Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing

-Advancing 11 clinical-stage assets across psychiatric conditions with Phase 2 data readouts in MDD and PTSD for each of its three lead candidates expected by mid-2023- ‍-Over $40 million in … Continued

October 07, 2021

Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officer

BALTIMORE and NEW YORK, Oct. 7, 2021 /PRNewswire/ — Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, announced the appointment of Doug Schenkel as Chief … Continued

Archives

© 2024 Windham Venture Partners 500 Fifth Avenue, Suite 3600, NY, NY 10110